

# News Releases

All Years



Search

GO

[Advanced Search](#)

**Nov 30, 2017**

## **Portola Pharmaceuticals to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting**

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that new data on the Company's first FDA-approved anticoagulant,...

**Nov 21, 2017**

## **Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch**

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has extended the...

**Nov 7, 2017**

## **Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association (AHA) Scientific Sessions 2017**

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that results of new sub-analyses of the APEX Study of betrixaban will be...

**Nov 6, 2017**

## **Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President and Chief Medical Officer**

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of John H. (Jack) Lawrence, M.D., as senior vice president and...

**Nov 6, 2017**

## **Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update**

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) will today report financial results and provide a corporate update for the quarter ended...

**Nov 3, 2017**

## **Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare Conference**

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Credit Suisse 26th...

**Oct 30, 2017**

## **Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 6**

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the...

**Oct 11, 2017**

## **Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness**

---

## **about the Persistent Risk of Blood Clots**

### **Portola and WTD Aim to Make VTE Protocol and Prevention a Priority Patient Safety Issue in Hospitals Across the United States**

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) announced today that it will be serving as a global partner for World Thrombosis Day to...

**Oct 3, 2017**

### **Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)**

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on September 27, 2017, the Compensation Committee of the Board of...

**Sep 12, 2017**

### **Portola Announces Pricing of Public Offering of Common Stock**

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today the pricing of its underwritten public offering of 6,350,000 shares of...

Show 10  per

page

 [1](#) ... [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) ... [25](#) 



---

<https://investors.portola.com/news-releases?!=10&o=80>